UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 337

Sortiert nach

Autologous Stem Cell Transplantation for T-Cell Lymphomas

Seminars in hematology, 2014, Vol.51 (1), p.59-66

2014

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Blood, 2010-10, Vol.116 (17), p.3227-3237

2010

Link zum Volltext

Verfügbarkeit prüfen

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma

Molecular cancer therapeutics, 2010-04, Vol.9 (4), p.963-975

2010

Link zum Volltext

Verfügbarkeit prüfen

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

Clinical cancer research, 2009-06, Vol.15 (12), p.4028-4037

2009

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma

Oncotarget, 2014-04, Vol.5 (7), p.1779-1792

2014

Link zum Volltext

Verfügbarkeit prüfen

A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity

HemaSphere, 2020-12, Vol.4 (6), p.e502-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Improving access to care and community health in Haiti with optimized community health worker placement

PLOS global public health, 2022, Vol.2 (5), p.e0000167-e0000167

2022

Link zum Volltext

Verfügbarkeit prüfen

Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5001-5007

2009

Link zum Volltext

Verfügbarkeit prüfen

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Blood, 2011-12, Vol.118 (23), p.5989-5995

2011

Link zum Volltext

Verfügbarkeit prüfen

Autologous Stem Cell Transplantation for T-Cell Lymphomas: Management of T-Cell Lymphomas

Seminars in hematology, 2014, Vol.51 (1), p.59-66

2014

Link zum Volltext

Verfügbarkeit prüfen

Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation

Transplant immunology, 2003-07, Vol.11 (3), p.345-356

2003

Link zum Volltext

Verfügbarkeit prüfen

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Blood, 2010-06, Vol.115 (25), p.5202-5213

2010

Link zum Volltext

Verfügbarkeit prüfen

Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.417-419

2022

Link zum Volltext

Verfügbarkeit prüfen

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood, 2010-09, Vol.116 (9), p.1460-1468

2010

Link zum Volltext

Verfügbarkeit prüfen

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Blood, 2019-11, Vol.134 (Supplement_1), p.5619-5619

2019

Link zum Volltext

Verfügbarkeit prüfen

Monitoring the sustainable development goals through human rights accountability reviews

Bulletin of the World Health Organization, 2018-09, Vol.96 (9), p.627-633

2018

Link zum Volltext

Verfügbarkeit prüfen

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood, 2022-11, Vol.140 (Supplement 1), p.10137-10139

2022

Link zum Volltext

Verfügbarkeit prüfen

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Blood, 2022-11, Vol.140 (Supplement 1), p.397-399

2022

Link zum Volltext

Verfügbarkeit prüfen

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment

Experimental cell research, 2014-11, Vol.328 (2), p.444-455

2014

Link zum Volltext

Verfügbarkeit prüfen

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

Oncogene, 2010-04, Vol.29 (16), p.2325-2336

2010

Link zum Volltext

Verfügbarkeit prüfen

Monitoring the sustainable development goals through human rights ccountability reviews/Suivi des objectifs de developpement durable a travers des examens du principe de responsabilite en matiere de droits de l'homme/Seguimiento de los objetivos de desarrollo sostenible mediante revisiones de la responsabilidad en materia de derechos humanos

Bulletin of the World Health Organization, 2018-09, Vol.96 (9), p.627

2018

Link zum Volltext

Verfügbarkeit prüfen

International Law and Chemical, Biological, Radio-Nuclear (CBRN) Events: Towards an All-Hazards Approach

1, 2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 337

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(316)
Mit Volltextzugriff
(322)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Autologous Stem Cell Transplantation for T-Cell Lymphomas

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma

A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity

Improving access to care and community health in Haiti with optimized community health worker placement

Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Autologous Stem Cell Transplantation for T-Cell Lymphomas: Management of T-Cell Lymphomas

Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Non-Restrictive Diet Does Not Increase Infections in Patients with Neutropenia after Stem Cell Transplantation: Final Analysis of the Neutrodiet Multicenter, Randomized Trial

PI3K/p110δ is a novel therapeutic target in multiple myeloma

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Monitoring the sustainable development goals through human rights accountability reviews

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

International Law and Chemical, Biological, Radio-Nuclear (CBRN) Events: Towards an All-Hazards Approach

Suchergebnisse filtern